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Introduction
To date, vaginal intercourse is the most common route for HIV
transmission and accounts for more than 80% of new infections
in women worldwide [1]. Nearly 10 years ago, in 2008, Swiss
experts recommended that suppressive ART could provide effective
and sufficient protection to allow unprotected sexual intercourse
[2]. More than 8 years of clinical experience did not change this
statement, but rather, confirmed it [3]. Today we know that the
HIV transmission risk between sero-discordant couples, in which
the infected partner is receiving effective antiretroviral therapy
(ART), remains very low [4]. This has changed the landscape of
HIV medicine, especially for HIV-infected women who wish to
become pregnant with an HIV-negative partner in a natural way,
not dependent on artificial insemination.
In addition, to better define the role of ART for HIV prevention,
the US National Institutes for Health (NIH) supported the
randomised clinical trial, HPTN 052, to evaluate the benefit of
early ART initiation for prevention of HIV transmission in sero-
discordant couples [5]. The results showed that earlier treatment
initiation reduced HIV transmissions by 96%.
With this use of ART as a preventative tool, the exciting news for
HIV sero-discordant couples is that HIV transmission to sexual
partners is extremely low if HIV viral load is fully supressed; the
era of condom use with a regular partner after exclusion of other
sexually transmitted infections seems to have passed [4-6].
However, what are the future challenges for this ‘post-condom
era’? Are we missing an important point?
The HPTN 052 results imply that HIV-positive women need to
be less concerned about using barrier methods such as male or
female condoms while living in a stable partnership and being on
ART with an undetectable viral load. The same situation applies
for a woman living with an HIV-positive male partner who remains
adherent to his treatment and is virologically suppressed.
However, using ART as prevention for HIV transmission does not
consider the very important issue of access to effective
contraceptives for women who want to prevent a pregnancy . If
male condoms become less important in terms of transmission they
will be less likely to be used in stable partnerships. Birth control
is an important part of women‘s well-being and autonomy during
the reproductive phase of their lives [7]. Worldwide, male condoms
remain the predominant contraceptive method despite the absence
of clear restrictions on hormonal contraception and intrauterine
devices for women living with HIV [8]. This relates to the
inexpensive and easily accessible nature of male condoms as
contraceptives as well as their protective effect against other
sexually transmitted infections. When counselling on specific
contraceptive methods for women with HIV, healthcare providers
must discuss all available possibilities and in particular, inform
women about the failure risk of hormonal methods due to
drug–drug interaction with ART. Hormonal contraception (HC)
includes combined hormones (progestin and oestrogen) delivered
as a daily pill, vaginal ring and transdermal patch, or progestin
only as an oral pill, injectable, subcutaneous implants and within
intrauterine devices. There are several concerns regarding drug–
drug interactions between HC and ART and reduced efficacy [9].
HIV-infected women using combined HC and efavirenz-,
nevirapine- or ritonavir-containing ART should be informed about
the possibility of decreased contraceptive efficacy [10,11]. If
condoms are omitted, which would have provided an additional
contraceptive effect, the uncertainty about efficacy of hormonal
products when in combination with ART becomes more important.
What problems may be caused by contraceptive
failure?
Following a global online community survey of 94 countries, 56.7%
of women living with HIV reported an unplanned pregnancy [12].
Unintended pregnancies (UP) carry a high risk and immense
burden of morbidity and even mortality for women, especially if
they have to undergo unsafe abortions in resource-poor areas or
where abortion is illegal [13-16]. Worldwide, as many as 74 million
UPs occur annually and 30% of these are due to either method-
or user-related contraceptive failures [17]. In circumstances when
condoms might not be used for onward transmission of HIV in
stable partnerships, it remains essential to avoid any UPs and
adverse outcomes with regards to maternal physical and
psychological health. We should be aware to never forget this
important issue when we talk about ART as prevention for HIV
transmission.
Conclusion
The preventive effect of ART in terms of onward HIV transmission,
as well as scaling up treatment as prevention worldwide, will
inevitably lead to less condom use and expose young women to
a higher risk for UP. We have now to evaluate the consequences
of behaviour change with respect to condom use in a broader
context, including other sexually transmitted infections and UP.
Where do we go from here? The major challenge is the
implementation of effective and sustained contraception use for
women living with HIV or living with an HIV-positive partner that
takes their type of ART and individual family planning into account.
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